ACLX Company Profile and Key Details

ACLX has shown mixed momentum, gaining 11.25% over the past week and -17.04% over the past quarter, though year-to-date performance is up 10.69%. Short-term trend indicators are mixed aligned (SMA20 -1.83%, SMA50 -1.71%, SMA200 -6.7%). The stock’s 14-day RSI is 45.1 (neutral), while the ATR of 3.14 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -28.84% below its high and over 39.87% above its low. Average 10-day trading volume of 718.19 thousand shares is below the 3-month average of 1.02 million, indicating normal recent market interest.

Arcellx, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $31.45. This means the shares are trading above this model’s fair value.

Arcellx, Inc. (NASDAQ:ACLX) closed at $66.94 USD, losing -$2.44 (-3.52%) from the previous close of $69.38. The stock is currently mid-range between its 52-week high and low $47.86 and $94.07. With a market capitalization of about $3.87 billion, Arcellx, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 1.06 million shares, in line with its 52-week average. Headquartered in Redwood City, MD, Arcellx, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rami Elghandour, the company employs approximately 163 people and listed since February 04, 2022. Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.

Arcellx, Inc. has 57.82 million shares outstanding. The public float is 39.46 million shares, elevated short interest at 21.52% of float. This equals 9.12 million shares. The short ratio is 9.98 days. Institutional investors hold 119.3% of the float. Insiders own 12.81%. New Enterprise Associates 15, L.P. holds 6.75 million shares, Novo Holdings A/S has 4.02 million shares and SR ONE CAPITAL MANAGEMENT, LLC has 1.66 million shares. Over the past six months, insider transactions show net selling. They sold 54.74 thousand shares across 13 transactions.

Arcellx, Inc. generated EPS of -$3.92 over the past year. Five-year average earnings growth is -31.14%. Wall Street analysts project EPS growth of 2.17% annually over the next five years. The latest quarter delivered EPS of -$0.99. The next quarter is forecast at -$1.04. Next year's EPS is expected at $9.89. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $133.00 to $88.00. The high target offers 98.69% upside. The low target suggests 31.46% downside. The mean target is $113.33. This offers 69.3% upside. Arcellx, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 3.13%. The prior quarter beat by -8.74%. Over the last six quarters, Apple has recorded several small beats. These include -5.56% in August 08, 2024.

Arcellx, Inc. trades at a P/E ratio of -17.57, slightly below the S&P 500 average, with a price-to-sales ratio of 108.98 and a price-to-book ratio of 8.69 trading at moderately above to book value. The P/FCF stands at -19.45, also below market averages.

Our AI price prediction model suggests that Arcellx, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.9%, with price expected at $72.23 by February 18, 2026, within a range of $70.10 to $74.57 3-Month Outlook: Projected rise of 13.89%, reaching $76.24 by May 05, 2026, with a range of $74.30 to $78.63. 1-Year Outlook: Projected gain of 31.15%, with price at $87.79 by February 04, 2027, within a range of $84.29 to $92.29.

Arcellx, Inc. (NASDAQ:ACLX) shares are up 10.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcellx, Inc. trading at a premium to the broader market with a P/E of -17.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $76.26, suggesting 13.92% upside. Our AI forecast model points to short-term strength (7.9% over two weeks), a medium-term rise (13.89% over three months), and a longer-term gain (31.15% over one year), with expected trading ranges indicating moderate volatility.